Hemophilia A - Symptoms, Causes, Treatment & Prevention

📅 Updated: April 2026 ⏱️ 7 min read ✅ Medically reviewed
```html Hemophilia A – Comprehensive Medical Guide

Hemophilia A – A Comprehensive Medical Guide

Overview

Hemophilia A is a hereditary bleeding disorder caused by a deficiency or dysfunction of clotting factor VIII (FVIII). Without enough functional FVIII, blood does not clot properly, leading to prolonged bleeding after injury, surgery, or even spontaneously.

It is the most common type of hemophilia, accounting for roughly 80‑85% of all cases. The condition follows an X‑linked recessive inheritance pattern, which means it primarily affects males, while females are usually carriers.

  • Prevalence: Approximately 1 in 5,000 male births worldwide have hemophilia A. In the United States, the CDC estimates about 20,000 people live with the disorder, of which > 95% are males.
  • Age of presentation: Symptoms typically appear in infancy or early childhood, often when a toddler experiences a deep bruise or prolonged bleeding from a minor cut.
  • Severity spectrum: Severity is classified by the level of factor VIII activity in the blood:
    • Severe: <10 % of normal activity
    • Moderate: 5‑10 % of normal activity
    • Mild: 5‑40 % of normal activity

Symptoms

Symptoms vary with severity but generally relate to the inability to form stable clots. Below is a complete list with brief descriptions.

Bleeding episodes

  • Spontaneous joint bleeds (hemarthrosis): Most common in severe disease; blood accumulates in the knee, ankle, or elbow, causing swelling, warmth, and limited motion.
  • Muscle bleeds: Deep, painful, sometimes presenting as a rapid increase in limb circumference.
  • Prolonged bleeding after minor cuts or dental work: Bleeding may continue for several hours or days.
  • Nosebleeds (epistaxis): Frequent and difficult to stop.
  • Gum bleeding: Often seen after brushing or dental procedures.
  • Hematuria: Blood in the urine, usually from bladder or kidney bleeding.
  • Gastrointestinal bleeding: Can present as melena or hematochezia, especially after trauma or ulcer disease.
  • Intracranial hemorrhage: Rare but life‑threatening; may cause headache, vomiting, seizures, or loss of consciousness.

Other signs

  • Easy bruising (large, dark bruises from low‑impact injuries).
  • Swelling and warmth around joints without obvious trauma.
  • Prolonged bleeding after vaccinations or circumcision in infants.

Causes and Risk Factors

Genetic cause

Hemophilia A results from mutations in the F8 gene located on the X chromosome (Xq28). Over 2,000 different mutations have been identified, including:

  • Large deletions or inversions (most common in severe cases).
  • Point mutations that affect protein synthesis.
  • Missense mutations that produce a dysfunctional FVIII protein.

Inheritance patterns

  • Classic X‑linked recessive: A carrier mother has a 50 % chance of passing the affected X chromosome to each son (who will have hemophilia) and a 50 % chance of passing it to each daughter (who becomes a carrier).
  • De novo mutations: Approximately 30 % of cases arise from a new mutation in the father’s sperm or mother’s egg, meaning there is no family history.

Risk factors

  • Male sex (because males have only one X chromosome).
  • Family history of hemophilia or known carrier status.
  • Ethnic groups with higher carrier frequencies (e.g., certain European populations).
  • Advanced maternal age marginally increases the chance of a de novo mutation.

Diagnosis

Diagnosis combines clinical suspicion with specific laboratory tests.

Screening tests

  • APTT (Activated Partial Thromboplastin Time): Prolonged in hemophilia A because it measures the intrinsic coagulation pathway where FVIII operates.
  • PT (Prothrombin Time): Usually normal, helping differentiate hemophilia from other clotting disorders.

Confirmatory tests

  • Factor VIII activity assay: Quantifies FVIII levels (%) and classifies severity.
  • Factor VIII inhibitor assay (Bethesda assay): Detects antibodies that neutralize infused FVIII—important before starting replacement therapy.
  • Genetic testing: DNA analysis of the F8 gene confirms the specific mutation, assists with genetic counseling, and allows carrier testing.

Additional evaluations

  • Joint imaging (X‑ray, MRI, or ultrasound) if hemarthrosis is suspected, to assess early joint damage.
  • Comprehensive medical history to identify bleeding patterns and family pedigree.

Treatment Options

Treatment aims to prevent bleeding, stop active bleeds, and maintain joint health. Advances in therapy have dramatically improved life expectancy, allowing many patients to live normal lifespans.

Replacement therapy

  • Plasma‑derived FVIII concentrates: Extracted from human plasma; purified and viral‑inactivated.
  • Recombinant FVIII products: Produced using genetically engineered cells (e.g., Advate®, Kogenate®, Eloctate®). These have a very low risk of pathogen transmission.
  • Extended half‑life (EHL) products: Modified to stay in circulation longer (e.g., efmoroctocog alfa, dalcinonacog alfa), allowing less frequent dosing.

Prophylactic regimens

For patients with severe disease, routine prophylaxis (regular infusions 2‑3 times per week) reduces joint bleeds by up to 95 % (World Federation of Hemophilia, 2023). Dosing is individualized based on activity level, pharmacokinetics, and lifestyle.

Bypassing agents

When inhibitors develop (≈30 % of severe hemophilia A patients), FVIII replacement becomes ineffective. Bypassing agents such as:

  • Activated prothrombin complex concentrates (aPCC; e.g., FEIBA®)
  • Recombinant activated factor VII (rFVIIa; e.g., NovoSeven®)

are used to achieve hemostasis.

Non‑replacement therapies

  • Emicizumab (Hemlibra®): A bispecific monoclonal antibody that bridges activated factor IX and X, mimicking FVIII function. It can be given subcutaneously once weekly or less frequently, and works even in the presence of inhibitors.
  • Gene therapy (ongoing trials): Early-phase studies using adeno‑associated virus (AAV) vectors show sustained FVIII expression; FDA approval is expected within the next few years.

Supportive measures

  • Tranexamic acid (antifibrinolytic) for mucosal bleeding or dental procedures.
  • Physical therapy and orthopaedic care to protect joints.
  • Vaccination against hepatitis A, B, and hepatitis C (especially important for patients previously exposed to plasma products).

Living with Hemophilia A

Daily management tips

  • Maintain a treatment log: Record infusion dates, dosages, and bleed episodes. This helps the care team adjust prophylaxis.
  • Regular joint assessments: Schedule physiotherapy or orthopaedic visits at least annually.
  • Stay active safely: Low‑impact activities (swimming, cycling, walking) improve joint health without high injury risk. Avoid contact sports unless prophylaxis is optimized.
  • Dental hygiene: Brush gently, floss with care, and inform the dentist of hemophilia status. Prophylactic FVIII before dental work reduces bleeding.
  • Home infusion training: Most patients (or a caregiver) learn to self‑infuse factor concentrate, enabling rapid treatment of bleeds.
  • Emergency card: Carry a medical identification card that lists diagnosis, current medication, and emergency contact.
  • Nutrition: Adequate calcium and vitamin D support bone health; a balanced diet helps maintain a healthy weight, reducing joint stress.

Mental and social wellbeing

Living with a chronic bleeding disorder can be stressful. Consider:

  • Connecting with hemophilia support groups (e.g., National Hemophilia Foundation).
  • Accessing counseling services for anxiety or depression.
  • Planning for school or work accommodations, such as allowing extra time for injections.

Prevention

Because hemophilia A is genetic, it cannot be prevented in the traditional sense. However, several strategies reduce bleeding risk and improve outcomes.

  • Genetic counseling: Recommended for carrier females and families planning pregnancy. Prenatal testing (chorionic villus sampling or amniocentesis) can detect the F8 mutation.
  • Early prophylaxis: Initiating regular factor replacement in infancy dramatically lowers the incidence of joint disease.
  • Avoidance of high‑risk activities: Use protective gear (helmets, padding) when engaged in sports.
  • Prompt treatment of minor bleeds: Early infusion prevents progression to larger joint hemorrhages.
  • Vaccinations and infection control: Protect against hepatitis and HIV, especially in regions where plasma‑derived products are still used.

Complications

If bleeding is not adequately controlled, several serious complications may develop.

Joint disease (hemophilic arthropathy)

Repeated hemarthrosis leads to chronic synovitis, cartilage loss, and ultimately osteoarthritis. Up to 70 % of severe hemophilia patients develop clinically significant joint disease by age 30 without prophylaxis.

Inhibitor development

Neutralizing antibodies against infused FVIII develop in 20‑30 % of severe cases, making standard replacement ineffective and increasing morbidity.

Intracranial hemorrhage (ICH)

Although rare (<1 % of bleeds), ICH carries a mortality rate of 25‑30 % and requires immediate intervention.

Chronic pain and reduced mobility

Joint damage and muscle bleeds can cause persistent pain, limiting daily activities and affecting quality of life.

Infections

Historically, plasma‑derived products transmitted hepatitis B, C, and HIV. Modern purification and viral inactivation have made this risk negligible in countries using recombinant products, but vigilance remains important.

Psychosocial impact

Fear of bleeding, school or work absenteeism, and treatment burden can lead to anxiety, depression, and social isolation.

When to Seek Emergency Care

Call 911 or go to the nearest emergency department immediately if you experience any of the following:
  • Severe, uncontrolled bleeding that does not stop after applying pressure for 10 minutes.
  • Bleeding into a joint or muscle that causes rapid swelling, severe pain, or loss of function.
  • Signs of internal bleeding: sudden abdominal pain, vomiting blood, black/tarry stools, or blood in urine.
  • Head injury followed by confusion, vomiting, severe headache, seizures, or loss of consciousness – possible intracranial hemorrhage.
  • Bleeding that occurs despite recent administration of factor VIII (possible inhibitor activity).
  • High fever with chills after a recent infusion – could indicate an allergic reaction or infection.

Prompt medical attention can be life‑saving and may prevent long‑term complications.

References

```

⚠️ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References